Indiana University Research AND Technology Corporation
发明人:
PELUS, Louis M.,HOGGATT, Jonathan,SINGH, Pratibha
申请号：
ZA201804932
公开号：
ZA201804932B
申请日:
2018.07.23
申请国别(地区):
ZA
年份:
2019
代理人:
摘要：
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 re-ceptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to in- crease viral-mediated gene transduction efficacy into HSPC.
